#	Pagina
attuale pagina	/open-fp7/projects/88202/index.html

TARCC

Targeting alpha-particle emitting radionuclides to combat cancer

Coordinatore	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Ms. Nome: Marianne Cognome: Desmedt Email: send email Telefono: +33 2 40 35 06 69 Fax: +33 2 40 47 77 01
Nazionalità Coordinatore	France [FR]
Sito del progetto	http://www.tarcc.org/
Totale costo	4˙112˙800 €
EC contributo	3˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-01-01 - 2011-06-30

Partecipanti

#	participant	country	role
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Ms. Nome: Marianne Cognome: Desmedt Email: send email Telefono: +33 2 40 35 06 69 Fax: +33 2 40 47 77 01	FR (PARIS)	coordinator
2	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Mr. Nome: Cedric Cognome: Bosaro Email: send email Telefono: +33 1 44 96 51 82 Fax: +33 1 44 96 49 14	FR (PARIS)	participant
3	GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Margareta Cognome: Ahlqwist Email: send email Telefono: +46 31 786 5345 Fax: +46 31 786 4355	SE (GOETEBORG)	participant
4	INSERM - TRANSFERT SA Organization address address: Rue Watt 7 city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Louis Cognome: Jammayrac Email: send email Telefono: +33 1 55 03 01 01 Fax: +33 1 55 03 01 60	FR (PARIS)	participant
5	ION BEAM APPLICATIONS SA Organization address address: Chemin du Cyclotron, 3 city: LOUVAIN LA NEUVE postcode: 1348 contact info Titolo: Dr. Nome: Richard Cognome: Zimmermann Email: send email Telefono: +33 1 69 85 70 50 Fax: +33 1 69 85 74 75	BE (LOUVAIN LA NEUVE)	participant
6	JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION Organization address address: Rue de la Loi 200 city: BRUSSELS postcode: 1049 contact info Titolo: Dr. Nome: Jacqueline Cognome: Ribeiro Email: send email Telefono: +49 7247 951 356 Fax: +49 7247 95199678	BE (BRUSSELS)	participant
7	KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN Organization address address: ISMANINGER STRASSE 22 city: MUENCHEN postcode: 81675 contact info Titolo: Ms. Nome: Inge Cognome: Linder Email: send email Telefono: +49 89 4140 4529 Fax: +49 89 41404996	DE (MUENCHEN)	participant
8	MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 contact info Titolo: Mr. Nome: Holger Cognome: Baumann Email: send email Telefono: +49 511 532 6034 Fax: +49 511 532 6032	DE (HANNOVER)	participant
9	UNIVERSITAETSKLINIKUM FREIBURG Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Gerhard Cognome: Henninger Email: send email Telefono: 497613000000 Fax: 497613000000	DE (FREIBURG)	participant
10	UNIVERSITAETSSPITAL BASEL Organization address address: HEBELSTRASSE 32 city: BASEL postcode: 4031 contact info Titolo: Ms. Nome: Rita Cognome: Ziegler Email: send email Telefono: +41 61 265 22 25 Fax: +41 61 265 26 50	CH (BASEL)	participant
11	UNIVERZITETNI KLINICNI CENTER LJUBLJANA Organization address address: ZALOSKA CESTA 002 city: LJUBLJANA postcode: 1000 contact info Titolo: Mr. Nome: Bojan Cognome: Uran Email: send email Telefono: +386 1 522 2191 Fax: +386 1 522 1234	SI (LJUBLJANA)	participant

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

colloids radionuclides cancer dosimetry cells small alpha size tissues emitting tumours nano toxicity

Obiettivo del progetto (Objective)

'This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting technology based on specific targeting agents (recombinant antibody fragments and synthetic peptides), pretargeting approaches and nano-colloids especially designed to deliver alpha-emitting radionuclides to cancer cells after local or systemic administration. The concept of in situ generator, that allows the use of longer half-life parents of alpha-emitting radionuclides will be developed. Several approaches to prevent the release of radionuclides after parent isotope disintegration, including encapsulation in nano-colloids, are proposed. Improved targeting methods will be tested in animal models of small-size tumours and associated dosimetry (including micro-dosimetry) and toxicity studies will be performed. The final goal of the project will be to propose one or several new products for targeted delivery of alpha-emitting radionuclides for clinical development.'

Introduzione (Teaser)

European researchers wished to address the challenge of cancer therapy by developing pharmaceuticals coupled to alpha-emitting radionuclides. The TARCC project's proposed approach envisioned site-specific tumour eradication without toxicity to healthy tissues.